[Form 4] Akero Therapeutics, Inc. Insider Trading Activity
Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity. The filing shows an acquisition of 3,000 common shares associated with a stock option having a conversion/exercise price of $7.009, and a sale of 3,000 common shares at $47.457. Following the reported transactions the filing shows she beneficially owned 9,398 shares of common stock directly. The disclosure also states that the related options are vested and currently exercisable.
Jane Henderson, una direttrice di Akero Therapeutics (AKRO), ha segnalato operazioni insider in data 08/12/2025 che evidenziano attivit脿 collegate su strumenti non derivati e derivati. La comunicazione riporta l'acquisto di 3.000 azioni ordinarie legate a un'opzione con prezzo di conversione/esercizio di $7.009 e la vendita di 3.000 azioni ordinarie a $47.457. Dopo le operazioni indicate, la dichiarazione mostra che deteneva direttamente in modo beneficiario 9.398 azioni ordinarie. Il documento precisa inoltre che le opzioni correlate sono acquisite e attualmente esercitabili.
Jane Henderson, una directora de Akero Therapeutics (AKRO), inform贸 operaciones internas con fecha 08/12/2025 que muestran actividad vinculada en instrumentos no derivados y derivados. El informe refleja la adquisici贸n de 3.000 acciones ordinarias asociadas a una opci贸n con precio de conversi贸n/ejercicio de $7.009 y la venta de 3.000 acciones ordinarias a $47.457. Tras las operaciones notificadas, el documento indica que pose铆a de forma beneficiaria y directa 9.398 acciones ordinarias. La declaraci贸n tambi茅n se帽ala que las opciones relacionadas est谩n adquiridas y actualmente ejercitables.
鞎勳紑搿� 韰岆澕頁嫳鞀�(AKRO)鞚� 鞚挫偓 鞝滌澑 項崝鞀潃 08/12/2025鞛� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨溂氅�, 牍勴寣靸濎儊頀� 氚� 韺岇儩靸來拡瓿� 鞐瓣硠霅� 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞝勴櫂/頄夓偓臧�瓴╈澊 $7.009鞚� 鞀ろ啞鞓奠厴瓿� 甏�霠悳 3,000 氤错喌欤� 旆摑 氚� $47.457鞐� 3,000 氤错喌欤� 毵る弰臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 攴鸽厐電� 歆侅爲鞝侅溂搿� 鞁れ鞝� 鞚挫澋鞚� 臧�歆� 9,398 欤检潣 氤错喌欤茧ゼ 氤挫湢頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 霕愴暅 甏�霠� 鞓奠厴鞚� 鞚措 旆摑霅橃柎 順勳灛 頄夓偓 臧�電ロ暅 靸來儨鞚措澕瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Jane Henderson, une directrice d'Akero Therapeutics (AKRO), a d茅clar茅 des transactions d'initi茅s dat茅es du 08/12/2025 indiquant des op茅rations li茅es sur des instruments non d茅riv茅s et d茅riv茅s. Le d茅p么t fait 茅tat de l'acquisition de 3 000 actions ordinaires li茅es 脿 une option avec un prix de conversion/exercice de $7.009, et de la vente de 3 000 actions ordinaires 脿 $47.457. 脌 la suite des op茅rations signal茅es, le d茅p么t indique qu'elle d茅tenait directement 脿 titre b茅n茅ficiaire 9 398 actions ordinaires. La d茅claration pr茅cise 茅galement que les options concern茅es sont acquises et actuellement exer莽ables.
Jane Henderson, eine Direktorin von Akero Therapeutics (AKRO), meldete Insider-Transaktionen vom 08/12/2025, die verkn眉pfte Aktivit盲ten mit nichtderivativen und derivativen Instrumenten zeigen. Die Meldung weist den Erwerb von 3.000 Stammaktien im Zusammenhang mit einer Aktienoption mit einem Umtausch-/Aus眉bungspreis von $7.009 sowie den Verkauf von 3.000 Stammaktien zu $47.457 aus. Nach den gemeldeten Transaktionen gab die Meldung an, dass sie direkt wirtschaftlich 9.398 Stammaktien besa脽. Die Offenlegung stellt au脽erdem klar, dass die betreffenden Optionen unverfallbar und derzeit aus眉bbar sind.
- None.
- None.
Insights
TL;DR: Director exercised options linked to 3,000 shares and sold 3,000 shares; transactions appear routine and not clearly material.
The Form 4 shows a simultaneous acquisition tied to options at a $7.009 conversion/exercise price and a contemporaneous sale of 3,000 shares at $47.457. After these entries the filer is reported as beneficially owning 9,398 shares. The filing also confirms the options are vested and exercisable. This pattern is consistent with an option exercise plus sale; the absolute amounts disclosed are modest and the filing contains no indication of broader corporate developments.
TL;DR: The disclosure is clear and timely: a director recorded option-related activity and a matching sale; governance transparency maintained.
The report identifies the reporting person as a director and indicates the filing was made by one reporting person. It lists both non-derivative and derivative entries tied to 3,000 shares and notes the options are vested and exercisable. From a governance viewpoint, the filing meets Section 16 reporting requirements by disclosing the exercise/sale activity; no additional governance concerns or material changes are disclosed in this filing.
Jane Henderson, una direttrice di Akero Therapeutics (AKRO), ha segnalato operazioni insider in data 08/12/2025 che evidenziano attivit脿 collegate su strumenti non derivati e derivati. La comunicazione riporta l'acquisto di 3.000 azioni ordinarie legate a un'opzione con prezzo di conversione/esercizio di $7.009 e la vendita di 3.000 azioni ordinarie a $47.457. Dopo le operazioni indicate, la dichiarazione mostra che deteneva direttamente in modo beneficiario 9.398 azioni ordinarie. Il documento precisa inoltre che le opzioni correlate sono acquisite e attualmente esercitabili.
Jane Henderson, una directora de Akero Therapeutics (AKRO), inform贸 operaciones internas con fecha 08/12/2025 que muestran actividad vinculada en instrumentos no derivados y derivados. El informe refleja la adquisici贸n de 3.000 acciones ordinarias asociadas a una opci贸n con precio de conversi贸n/ejercicio de $7.009 y la venta de 3.000 acciones ordinarias a $47.457. Tras las operaciones notificadas, el documento indica que pose铆a de forma beneficiaria y directa 9.398 acciones ordinarias. La declaraci贸n tambi茅n se帽ala que las opciones relacionadas est谩n adquiridas y actualmente ejercitables.
鞎勳紑搿� 韰岆澕頁嫳鞀�(AKRO)鞚� 鞚挫偓 鞝滌澑 項崝鞀潃 08/12/2025鞛� 雮措秬鞛� 瓯半灅毳� 鞁犼碃頄堨溂氅�, 牍勴寣靸濎儊頀� 氚� 韺岇儩靸來拡瓿� 鞐瓣硠霅� 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 鞝勴櫂/頄夓偓臧�瓴╈澊 $7.009鞚� 鞀ろ啞鞓奠厴瓿� 甏�霠悳 3,000 氤错喌欤� 旆摑 氚� $47.457鞐� 3,000 氤错喌欤� 毵る弰臧� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 攴鸽厐電� 歆侅爲鞝侅溂搿� 鞁れ鞝� 鞚挫澋鞚� 臧�歆� 9,398 欤检潣 氤错喌欤茧ゼ 氤挫湢頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 霕愴暅 甏�霠� 鞓奠厴鞚� 鞚措 旆摑霅橃柎 順勳灛 頄夓偓 臧�電ロ暅 靸來儨鞚措澕瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Jane Henderson, une directrice d'Akero Therapeutics (AKRO), a d茅clar茅 des transactions d'initi茅s dat茅es du 08/12/2025 indiquant des op茅rations li茅es sur des instruments non d茅riv茅s et d茅riv茅s. Le d茅p么t fait 茅tat de l'acquisition de 3 000 actions ordinaires li茅es 脿 une option avec un prix de conversion/exercice de $7.009, et de la vente de 3 000 actions ordinaires 脿 $47.457. 脌 la suite des op茅rations signal茅es, le d茅p么t indique qu'elle d茅tenait directement 脿 titre b茅n茅ficiaire 9 398 actions ordinaires. La d茅claration pr茅cise 茅galement que les options concern茅es sont acquises et actuellement exer莽ables.
Jane Henderson, eine Direktorin von Akero Therapeutics (AKRO), meldete Insider-Transaktionen vom 08/12/2025, die verkn眉pfte Aktivit盲ten mit nichtderivativen und derivativen Instrumenten zeigen. Die Meldung weist den Erwerb von 3.000 Stammaktien im Zusammenhang mit einer Aktienoption mit einem Umtausch-/Aus眉bungspreis von $7.009 sowie den Verkauf von 3.000 Stammaktien zu $47.457 aus. Nach den gemeldeten Transaktionen gab die Meldung an, dass sie direkt wirtschaftlich 9.398 Stammaktien besa脽. Die Offenlegung stellt au脽erdem klar, dass die betreffenden Optionen unverfallbar und derzeit aus眉bbar sind.
FAQ
What transactions did Jane Henderson report on Form 4 for AKRO?
How many AKRO shares does Jane Henderson beneficially own after the reported transactions?
What was the conversion/exercise price of the reported stock option?
Are the options reported by Jane Henderson exercisable?
What is Jane Henderson's relationship to Akero Therapeutics (AKRO)?
